

For adults with moderately to severely active

Crohn's disease (CD)

HEALING *is* POSSIBLE*

with Tremfya® (guselkumab)

There is no cure for CD.

In a clinical trial of patients receiving SC initial and maintenance dosing:

Clinical remission at week 12: 56% (400 mg). **Endoscopic response** at week 12: 34% (400 mg).

*40% (200 mg) and 31% (100 mg) achieved **endoscopic remission** at one year. Based on areas visualized on colonoscopy, which may not represent the deeper bowel layer or all areas.

Individual results may vary.
SC=subcutaneous (under the skin).

View inside for more details.

WHAT IS TREMFYA® (guselkumab)?

TREMFYA® is a prescription medicine used to treat adults with moderately to severely active Crohn's disease or ulcerative colitis.

SELECTED IMPORTANT SAFETY INFORMATION

TREMFYA® is not for everyone; only your healthcare provider can decide if it's right for you. Do not use if you are allergic to TREMFYA®. TREMFYA® is a prescription medicine that may cause serious side effects, including serious allergic reactions, infections, and liver problems. TREMFYA® affects your immune system. It may increase your risk of infections and lower your ability to fight them. Please read the Important Safety Information on pages 14-15 and the Medication Guide for TREMFYA® to learn more about these and other risks for TREMFYA®. Discuss any questions you have with your healthcare provider.

TREMFYA is the only IL-23 blocker to offer SELF-ADMINISTRATION FROM THE START *across both* CD and UC

For adults with moderately to severely active Crohn's disease (CD)

Tremfya® (guselkumab)

If your healthcare provider decides that you or a caregiver may be able to give your injections of TREMFYA at home, you should receive training on the right way to prepare and inject TREMFYA. Do not try to inject yourself until you have been trained by your healthcare provider.

How to take TREMFYA:

INITIAL DOSES

SC INJECTIONS under the skin

Your first 3 doses may be taken as 2 SC injections every 4 weeks.*

WEEK 0 400 MG | **WEEK 4** 400 MG | **WEEK 8** 400 MG

*Each 400 mg dosage will be given as two consecutive injections of 200 mg.

OR

INTRAVENOUS (IV) INFUSION through a vein in the arm

You may be given an IV infusion every 4 weeks at a healthcare facility. It takes at least 1 hour for each dose.

WEEK 0 200 MG | **WEEK 4** 200 MG | **WEEK 8** 200 MG

MAINTENANCE DOSES

SC INJECTIONS

The recommended maintenance doses are:

- 200 mg at week 12 and every 4 weeks thereafter

OR

- 100 mg at week 16 and every 8 weeks thereafter

WEEK 12 and every 4 weeks after — 200 MG

OR

WEEK 16 and every 8 weeks after — 100 MG

Your healthcare provider will prescribe the right dose for you. Use TREMFYA exactly as prescribed.

IMPORTANT: Read the detailed Instructions for Use (IFU) that comes with your TREMFYA medication for information on how to prepare and administer TREMFYA.

IL=interleukin; CD=Crohn's disease; UC=ulcerative colitis.

If you're starting TREMFYA subcutaneously, you may receive a TREMFYA Induction Pack.

Scan the QR code to discover resources designed to help you understand where and how to inject TREMFYA.

A dedicated Nurse Guide†—a registered nurse—is available for infusion and injection support.‡

Call: 1-833-WITHME1 (833-948-4631) Monday–Friday, 8:00 AM–11:00 PM ET.

Multilingual phone support is available.

†Nurse Guides do not provide medical advice. Please ask your doctor any questions you might have about your disease and treatment.

‡Your doctor is the best person to help you understand what to expect. Your Nurse Guide is also available, after you have talked with your doctor, if you have questions about infusions or injections.

SELECTED IMPORTANT SAFETY INFORMATION

TREMFYA® is not for everyone; only your healthcare provider can decide if it's right for you. Do not use if you are allergic to TREMFYA®. TREMFYA® is a prescription medicine that may cause serious side effects, including serious allergic reactions, infections, and liver problems. TREMFYA® affects your immune system. It may increase your risk of infections and lower your ability to fight them. Please read the Important Safety Information on pages 14-15 and the Medication Guide for TREMFYA® to learn more about these and other risks for TREMFYA®. Discuss any questions you have with your healthcare provider.

ADMINISTRATION OPTIONS *for* TREMFYA

Once you have had your first three initial doses, you will take TREMFYA as a subcutaneous injection.

After your healthcare provider decides how much medicine you'll be injecting, and how often, you can discuss which injection device may be appropriate for you.



Not actual size

200 mg/2 mL
TREMFYA PEN pictured


TREMFYA PEN

200 mg/2 mL OR 100 mg/mL

The TREMFYA PEN has a thin hidden needle with a viewing window and is available for 200 mg/2 mL or 100 mg/mL maintenance dosing.

The 200 mg/2 mL TREMFYA PEN is yellow and the 100 mg/mL TREMFYA PEN is teal.

OR



Not actual size

200 mg/2 mL prefilled syringe pictured

Prefilled Syringe

200 mg/2 mL OR 100 mg/mL

For those who do not prefer an injector, the single-dose prefilled syringe is available for 200 mg/2 mL or 100 mg/mL maintenance dosing.

The 200 mg/2 mL prefilled syringe is yellow and the 100 mg/mL prefilled syringe is teal.

The **One-Press patient-controlled injector** is available as an alternative device option. Talk to your healthcare provider about which administration option is right for you.

For adults with moderately to severely active Crohn's disease (CD)

Tremfya® (guselkumab)

~9/10

~9 out of 10 patients with CD or UC would choose **a subcutaneous injection pen** over an SC on-body injection device.*†‡

***TREMFYA does not offer an SC on-body injection device.**

†Based on a validated third-party 2025 market research survey‡ of 506 patients, including both bio-naïve (patients who were new to a biologic) and bio-experienced (patients who previously received a biologic).
This survey reflects participant opinions. It did not evaluate efficacy or safety. While these factors are important, there are additional considerations for selecting treatment. Talk to your healthcare provider about treatment options and what might be right for you.

‡**Survey question:** Please read each description carefully and select which one you would prefer to use for your Crohn's disease/ulcerative colitis.

UC=ulcerative colitis.

Learn more about injecting with TREMFYA by scanning this QR code.

Next: How can TREMFYA help?

SELECTED IMPORTANT SAFETY INFORMATION

TREMFYA® is not for everyone; only your healthcare provider can decide if it's right for you. Do not use if you are allergic to TREMFYA®. TREMFYA® is a prescription medicine that may cause serious side effects, including serious allergic reactions, infections, and liver problems. TREMFYA® affects your immune system. It may increase your risk of infections and lower your ability to fight them. Please read the Important Safety Information on pages 14-15 and the Medication Guide for TREMFYA® to learn more about these and other risks for TREMFYA®. Discuss any questions you have with your healthcare provider.

Why choose TREMFYA?

Some goals of managing Crohn's disease are to visibly improve the intestinal lining and to treat symptoms—TREMFYA (guselkumab) can help with both.

In a clinical trial, patients received TREMFYA as subcutaneous (SC) injections (under the skin), which started with 400 mg at weeks 0, 4, and 8, followed by either 100 mg every 8 weeks or 200 mg every 4 weeks.*

Results with **NO IV DOSING** from day 1

FAST ACTING AND LONG LASTING

Rapid results at 12 weeks

All patients started with SC doses of 400 mg

PATIENTS WHO ACHIEVED CLINICAL REMISSION



PATIENTS WHO ACHIEVED ENDOSCOPIC RESPONSE†




Decreases in abdominal pain and bowel movements were observed **as early as 4 weeks**.

Lasting results at 1 year

After initial SC doses, patients received 200 mg every 4 weeks or 100 mg every 8 weeks

PATIENTS WHO ACHIEVED CLINICAL REMISSION



Also, **59%** of patients on TREMFYA 100 mg SC maintenance doses achieved clinical remission.

PATIENTS WHO ACHIEVED ENDOSCOPIC RESPONSE†



Also, **39%** of patients on TREMFYA 100 mg SC maintenance doses achieved endoscopic response.

For adults with moderately to severely active Crohn's disease (CD)


Results with **NO IV DOSING** from day 1

SOME PATIENTS HAD VISIBLE HEALING OF THE INTESTINAL LINING

There is no cure for CD.

After initial SC doses, patients received 200 mg every 4 weeks or 100 mg every 8 weeks

PATIENTS WHO WERE IN ENDOSCOPIC REMISSION



Visible healing of the intestinal lining means endoscopic remission.

Endoscopic remission and endoscopic response are based on areas visualized on colonoscopy, which may not represent the deeper bowel layer or all areas.

Results with **NO IV DOSING** from day 1

AT 2 YEARS PATIENTS WERE IN CLINICAL REMISSION‡

After initial SC doses, patients received 200 mg every 4 weeks or 100 mg every 8 weeks



OF PATIENTS WERE IN CLINICAL REMISSION AT 2 YEARS

TREMFYA maintenance doses at 200 mg SC



OF PATIENTS WERE IN CLINICAL REMISSION AT 2 YEARS

TREMFYA maintenance doses at 100 mg SC

‡The same patients may not have been in remission at each timepoint. After 1 year, patients and healthcare providers knew that TREMFYA was used. This may have increased results.

Individual results may vary.

*Results are from a 48-week clinical trial of patients with moderately to severely active Crohn's disease: 225 patients started with TREMFYA 400 mg SC doses followed by 114 patients receiving TREMFYA 100 mg SC and 111 patients receiving TREMFYA 200 mg SC maintenance doses, and 115 patients received placebo.

†Endoscopic response means visible improvement of the intestinal lining.

SELECTED IMPORTANT SAFETY INFORMATION

TREMFYA® is not for everyone; only your healthcare provider can decide if it's right for you. Do not use if you are allergic to TREMFYA®. TREMFYA® is a prescription medicine that may cause serious side effects, including serious allergic reactions, infections, and liver problems. TREMFYA® affects your immune system. It may increase your risk of infections and lower your ability to fight them. Please read the Important Safety Information on pages 14-15 and the Medication Guide for TREMFYA® to learn more about these and other risks for TREMFYA®. Discuss any questions you have with your healthcare provider.

Why choose TREMFYA? (cont'd)

For adults with moderately to severely active Crohn's disease (CD)

Tremfya® (guselkumab)

TREMFYA was also studied in two identical trials, which started with doses of 200 mg administered **intravenously (IV)** through a vein in the arm.*


Individual results may vary.

Results from two trials starting with **IV DOSING**

RAPID RELIEF AT WEEK 12


Patients who achieved clinical remission at week 12

All patients started with IV doses of 200 mg every 4 weeks



Patients who achieved endoscopic response† at week 12

All patients started with IV doses of 200 mg every 4 weeks



Endoscopic response is based on areas visualized by endoscopy.

Talk to your healthcare provider to see if TREMFYA is right for you.

SEE THE FULL TREMFYA RESULTS

See how TREMFYA was studied against STELARA® in two trials.

Scan the QR code or visit tremfya.com/vs-stelara to get the details on the full results.

*Results are from two identical clinical trials of patients with moderately to severely active Crohn's disease. Trial 1: 285 patients started with TREMFYA 200 mg IV doses and 76 patients received placebo. Trial 2: 288 patients started with TREMFYA 200 mg IV doses and 72 patients received placebo.

†Endoscopic response means visible improvement of the intestinal lining.

Next: How does TREMFYA work?

SELECTED IMPORTANT SAFETY INFORMATION

TREMFYA® is not for everyone; only your healthcare provider can decide if it's right for you. Do not use if you are allergic to TREMFYA®. TREMFYA® is a prescription medicine that may cause serious side effects, including serious allergic reactions, infections, and liver problems. TREMFYA® affects your immune system. It may increase your risk of infections and lower your ability to fight them. Please read the Important Safety Information on pages 14-15 and the Medication Guide for TREMFYA® to learn more about these and other risks for TREMFYA®. Discuss any questions you have with your healthcare provider.

A DUAL-ACTING *treatment*[*†]

For adults with moderately to severely active Crohn's disease (CD)

Tremfya® (guselkumab)

TREMFYA is the only IL-23 blocker that works in two ways

- It targets a key component of inflammation called IL-23[*†]
- It binds to a target on the cells that make IL-23 called CD64[†‡]

1

TREMFYA targets IL-23, a key component of inflammation in CD.[*†]



2

TREMFYA also binds to a target on the cells that make IL-23 called CD64.[†‡]

Next: Learn about the legacy and safety of TREMFYA.

[*]Based on laboratory experiments using inflammatory cells.
[†]The clinical significance of these findings is unknown.
[‡]CD64 are proteins on the surface of certain immune cells, and these cells are the main producers of IL-23 in CD. Cells that do not have CD64 on their surface may also produce IL-23 but to a lesser extent.

"Only" based on approved selective IL-23 blockers for moderately to severely active CD as of September 2025.

Scan the QR code to learn more about TREMFYA.

CD64=cluster of differentiation 64.

SELECTED IMPORTANT SAFETY INFORMATION

TREMFYA® is not for everyone; only your healthcare provider can decide if it's right for you. Do not use if you are allergic to TREMFYA®. TREMFYA® is a prescription medicine that may cause serious side effects, including serious allergic reactions, infections, and liver problems. TREMFYA® affects your immune system. It may increase your risk of infections and lower your ability to fight them. Please read the Important Safety Information on pages 14-15 and the Medication Guide for TREMFYA® to learn more about these and other risks for TREMFYA®. Discuss any questions you have with your healthcare provider.



For adults with moderately to severely active Crohn's disease (CD)

Tremfya® (guselkumab)

TREMFYA LEGACY

15+ YEARS **of combined clinical research***

8+ YEARS **on the market across multiple indications**

*Based on a clinical trial of TREMFYA initiated in 2009.

POTENTIAL SIDE EFFECTS

Before starting TREMFYA, ask your healthcare provider about the benefits and risks of TREMFYA. TREMFYA has possible risks involved with treatment, so it's important to discuss them with your healthcare provider.

TREMFYA may cause serious side effects, including serious allergic reactions, infections, and liver problems.

The most common side effects of TREMFYA include:

- respiratory tract infections
- headache
- injection site reactions
- joint pain (arthralgia)
- diarrhea
- stomach flu (gastroenteritis)
- fungal skin infections
- herpes simplex infections
- stomach pain
- bronchitis
- feeling very tired (fatigue)
- fever (pyrexia)
- skin rash (rash)

These are not all the possible side effects of TREMFYA. See the Important Safety Information on pages 14-15 and talk to your healthcare provider about the benefits and risks of TREMFYA. Talk to your doctor for medical advice about side effects.

You may report side effects to the FDA at 1-800-FDA-1088.

SELECTED IMPORTANT SAFETY INFORMATION

TREMFYA® is not for everyone; only your healthcare provider can decide if it's right for you. Do not use if you are allergic to TREMFYA®. TREMFYA® is a prescription medicine that may cause serious side effects, including serious allergic reactions, infections, and liver problems. TREMFYA® affects your immune system. It may increase your risk of infections and lower your ability to fight them. Please read the Important Safety Information on pages 14-15 and the Medication Guide for TREMFYA® to learn more about these and other risks for TREMFYA®. Discuss any questions you have with your healthcare provider.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about TREMFYA®?

TREMFYA® is a prescription medicine that may cause serious side effects, including:

- **Serious Allergic Reactions.** Stop using TREMFYA® and get emergency medical help right away if you develop any of the following symptoms of a serious allergic reaction:
  - fainting, dizziness, feeling lightheaded (low blood pressure)
  - swelling of your face, eyelids, lips, mouth, tongue or throat
  - trouble breathing or throat tightness
  - chest tightness
  - skin rash, hives
  - itching
- **Infections.** TREMFYA® may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with TREMFYA® and may treat you for TB before you begin treatment with TREMFYA® if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with TREMFYA®.

  Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:
  - fever, sweats, or chills
  - muscle aches
  - weight loss
  - cough
  - warm, red, or painful skin or sores on your body different from your psoriasis
  - diarrhea or stomach pain
  - shortness of breath
  - blood in your phlegm (mucus)
  - burning when you urinate or urinating more often than normal
- **Liver Problems.** With the treatment of Crohn's disease or ulcerative colitis, your healthcare provider will do blood tests to check your liver before and during treatment with TREMFYA®. Your healthcare provider may stop treatment with TREMFYA® if you develop liver problems. Tell your healthcare provider right away if you notice any of the following symptoms:
  - unexplained rash
  - vomiting
  - tiredness (fatigue)
  - yellowing of the skin or the whites of your eyes
  - nausea
  - stomach pain (abdominal)
  - loss of appetite
  - dark urine

Do not use TREMFYA® if you have had a serious allergic reaction to guselkumab or any of the ingredients in TREMFYA®.

Before using TREMFYA®, tell your healthcare provider about all of your medical conditions, including if you:

- have any of the conditions or symptoms listed in the section **"What is the most important information I should know about TREMFYA®?"**
- have an infection that does not go away or that keeps coming back.
- have TB or have been in close contact with someone with TB.
- have recently received or are scheduled to receive an immunization (vaccine). You should avoid receiving live vaccines during treatment with TREMFYA®.
- are pregnant or plan to become pregnant. It is not known if TREMFYA® can harm your unborn baby.
  Pregnancy Registry: If you become pregnant during treatment with TREMFYA®, talk to your healthcare provider about registering in the pregnancy exposure registry for TREMFYA®. You can enroll by visiting www.mothertobaby.org/ongoing-study/tremfya-guselkumab, by calling 1-877-311-8972, or emailing *MotherToBaby@health.ucsd.edu*. The purpose of this registry is to collect information about the safety of TREMFYA® during pregnancy.
- are breastfeeding or plan to breastfeed. It is not known if TREMFYA® passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of TREMFYA®?

TREMFYA® may cause serious side effects. See "What is the most important information I should know about TREMFYA®?"

The most common side effects of TREMFYA® include: respiratory tract infections, headache, injection site reactions, joint pain (arthralgia), diarrhea, stomach flu (gastroenteritis), fungal skin infections, herpes simplex infections, stomach pain, bronchitis, feeling very tired (fatigue), fever (pyrexia), and skin rash.

These are not all the possible side effects of TREMFYA®. Call your doctor for medical advice about side effects.

Use TREMFYA® exactly as your healthcare provider tells you to use it.

Please read the full Prescribing Information, including Medication Guide, for TREMFYA® and discuss any questions that you have with your doctor.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Dosage Forms and Strengths: TREMFYA® is available as 100 mg/mL and 200 mg/2 mL for subcutaneous injection and as a 200 mg/20 mL (10 mg/mL) single dose vial for intravenous infusion.

cp-510994v2

SUPPORT *to help you*



SELECTED IMPORTANT SAFETY INFORMATION

TREMFYA® is not for everyone; only your healthcare provider can decide if it's right for you. Do not use if you are allergic to TREMFYA®. TREMFYA® is a prescription medicine that may cause serious side effects, including serious allergic reactions, infections, and liver problems. TREMFYA® affects your immune system. It may increase your risk of infections and lower your ability to fight them. Please read the Important Safety Information on pages 14-15 and the Medication Guide for TREMFYA® to learn more about these and other risks for TREMFYA®. Discuss any questions you have with your healthcare provider.

Once you and your doctor have decided that TREMFYA (guselkumab) is right for you, sign up for TREMFYA withMe.

Tremfya withMe

Get free, personalized support to help make it easier to start and stay on treatment.

Whether you need help understanding how to get your prescription filled or finding cost support options to help you pay for your treatment, TREMFYA withMe has everything you may need to help you start and stay on track.

TREMFYA withMe offers:

Dedicated Nurse Guide*

Your Nurse Guide is a registered nurse committed to providing personalized one-on-one support on your treatment journey, including preparing you for your starter and maintenance doses.†

Prescription and Cost Support

TREMFYA withMe can help you understand how to fill your prescription and find cost support options that may help you pay for TREMFYA.

Patient Portal

Get access to a personalized patient portal with helpful resources.

*Nurse Guides do not provide medical advice. Please ask your doctor any questions you might have about your disease and treatment.

The support and resources provided by TREMFYA withMe are not intended to provide medical advice, replace a treatment plan you receive from your doctor or nurse, or serve as a reason for you to start or stay on treatment.

†Your doctor is the best person to help you understand what to expect. Your Nurse Guide is also available, after you have talked with your doctor, if you have questions about infusions or injections.

Scan to sign up for patient support offered by TREMFYA withMe.

For adults with moderately to severely active Crohn's disease (CD)

Tremfya® (guselkumab)

DUAL ACTING*†

Blocks IL-23 and binds to a target on cells that make IL-23

*Based on laboratory experiments using inflammatory cells.
†The clinical significance of these findings is unknown.

INITIAL DOSING IN TWO WAYS

SC injection or IV infusion from the start

You and your healthcare provider will decide how you start TREMFYA for CD.

If your healthcare provider decides that you or a caregiver may be able to give your injections of TREMFYA at home, you should receive training on the right way to prepare and inject TREMFYA. Do not try to inject yourself until you have been trained by your healthcare provider.

VISIBLE HEALING

At one year, **1 out of 3** patients on TREMFYA (200 mg and 100 mg) achieved endoscopic remission.

There is no cure for CD.

Individual results may vary. Based on areas visualized on colonoscopy, which may not represent the deeper bowel layer or all areas. See page 7 for details.

Once you and your healthcare provider have decided that TREMFYA is right for you

Get free, personalized support

Tremfya withMe

Talk to your healthcare provider about TREMFYA.

Scan the QR code or visit TREMFYA.com to learn more.

SELECTED IMPORTANT SAFETY INFORMATION

TREMFYA® is not for everyone; only your healthcare provider can decide if it's right for you. Do not use if you are allergic to TREMFYA®. TREMFYA® is a prescription medicine that may cause serious side effects, including serious allergic reactions, infections, and liver problems. TREMFYA® affects your immune system. It may increase your risk of infections and lower your ability to fight them. Please read the Important Safety Information on pages 14-15 and the Medication Guide for TREMFYA® to learn more about these and other risks for TREMFYA®. Discuss any questions you have with your healthcare provider.

Johnson&Johnson

© Johnson & Johnson and its affiliates 2026 11/26 cp-501572v4